The Interleukin-33/ST2 Axis Enhances Lung-Resident CD14+ Monocyte Function in Patients with Non-Small Cell Lung Cancer

References

• Almatroodi SA, McDonald CF, Collins AL, Darby IA, Pouniotis DS. 2014. Blood classical monocytes phenotype is not altered in primary non-small cell lung cancer. World J Clin Oncol. 5:1078–87.
   PubMedGoogle Scholar
• Barrera L, Montes-Servin E, Barrera A, Ramirez-Tirado LA, Salinas-Parra F, Banales-Mendez JL, Sandoval-Rios M, Arrieta O. 2015. Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosis. Ann Oncol. 26:428–35.
   PubMed Web of Science ®Google Scholar
• Cai T, Qiu J, Ji Y, Li W, Ding Z, Suo C, Chang J, Wang J, He R, Qian Y, et al. 2019. IL-17-producing ST2(+) group 2 innate lymphoid cells play a pathogenic role in lung inflammation. J Allergy Clin Immunol. 143:229–44 e229.
   PubMed Web of Science ®Google Scholar
• Casciaro M, Cardia R, Di Salvo E, Tuccari G, Ieni A, Gangemi S. 2019. Interleukin-33 involvement in nonsmall cell lung carcinomas: an update. Biomolecules. 9:203.
   PubMed Web of Science ®Google Scholar
• Cayrol C, Girard JP. 2018. Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family. Immunol Rev. 281:154–68.
   PubMed Web of Science ®Google Scholar
• Dagher R, Copenhaver AM, Besnard V, Berlin A, Hamidi F, Maret M, Wang J, Qu X, Shrestha Y, Wu J, et al. 2020. IL-33-ST2 axis regulates myeloid cell differentiation and activation enabling effective club cell regeneration. Nat Commun. 11:4786.
   PubMed Web of Science ®Google Scholar
• Dong Y, Ming B, Gao R, Mo Q, Wu X, Zheng F, Zhong J, Dong L. 2022. The IL-33/ST2 axis promotes primary Sjogren’s syndrome by enhancing salivary epithelial cell activation and type 1 immune response. J Immunol. 208:2652–62.
   PubMed Web of Science ®Google Scholar
• Drake LY, Kita H. 2017. IL-33: biological properties, functions, and roles in airway disease. Immunol Rev. 278:173–84.
   PubMed Web of Science ®Google Scholar
• Du XX, Shi Y, Yang Y, Yu Y, Lou HG, Lv FF, Chen Z, Yang Q. 2018. DAMP molecular IL-33 augments monocytic inflammatory storm in hepatitis B-precipitated acute-on-chronic liver failure. Liver Int. 38:229–38.
   PubMed Web of Science ®Google Scholar
• Duma N, Santana-Davila R, Molina JR. 2019. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 94:1623–40.
   PubMed Web of Science ®Google Scholar
• Hayakawa M, Hayakawa H, Matsuyama Y, Tamemoto H, Okazaki H, Tominaga S. 2009. Mature interleukin-33 is produced by calpain-mediated cleavage in vivo. Biochem Biophys Res Commun. 387:218–22.
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr., Wu YL, Paz-Ares L. 2017. Lung cancer: current therapies and new targeted treatments. Lancet. 389:299–311.
   PubMed Web of Science ®Google Scholar
• Hu LA, Fu Y, Zhang DN, Zhang J. 2013. Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer. Asian Pac J Cancer Prev. 14:2563–66.
   PubMedGoogle Scholar
• Huang X, Yu H, Xie C, Zhou YL, Chen MM, Shi HL, Tang WF, Dong JC, Luo QL. 2022. Louki Zupa decoction attenuates the airway inflammation in acute asthma mice induced by ovalbumin through IL-33/ST2-NF-kappaB/gsk3beta/mtor signalling pathway. Pharm Biol. 60:1520–32.
   PubMed Web of Science ®Google Scholar
• Jiang W, Lian J, Yue Y, Zhang Y. 2021. IL-33/ST2 as a potential target for tumor immunotherapy. Eur J Immunol. 51:1943–55.
   PubMed Web of Science ®Google Scholar
• Jonna S, Subramaniam DS. 2019. Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update. Discov Med. 27:167–70.
   PubMed Web of Science ®Google Scholar
• Karagiannis F, Masouleh SK, Wunderling K, Surendar J, Schmitt V, Kazakov A, Michla M, Holzel M, Thiele C, Wilhelm C. 2020. LIpid-droplet formation drives pathogenic group 2 innate lymphoid cells in airway inflammation. Immunity. 52:620–34 e626.
   PubMed Web of Science ®Google Scholar
• Kwiecien I, Rutkowska E, Polubiec-Kownacka M, Raniszewska A, Rzepecki P, Domagala-Kulawik J. 2020. Blood monocyte subsets with activation markers in relation with macrophages in non-small cell lung cancer. Cancers (Basel). 12. doi:10.3390/cancers12092513
   Web of Science ®Google Scholar
• Li X, Lv Q, Feng Y, Gu Y, Xia R, Ma J, He H, Zhu Y. 2018. Interleukin-33, a potential cytokine expressed in tumor microenvironment involves in antitumor immunotherapy through facilitates CD8(+) T cells. J Interferon Cytokine Res. 38:491–99.
   PubMed Web of Science ®Google Scholar
• Li S, Wang Z, Zhang G, Fu J, Zhang X. 2019. Interleukin-7 promotes lung-resident CD14(+) monocytes activity in patients with lung squamous carcinoma. Int Immunopharmacol. 67:202–10.
   PubMed Web of Science ®Google Scholar
• Miller JE, Lingegowda H, Symons LK, Bougie O, Young SL, Lessey BA, Koti M, Tayade C. 2021. IL-33 activates group 2 innate lymphoid cell expansion and modulates endometriosis. JCI Insight. 6. doi:10.1172/jci.insight.149699
   Web of Science ®Google Scholar
• Ramirez-Moral I, Blok DC, Bernink JH, Garcia-Laorden MI, Florquin S, Boon L, Van’t Veer C, Mack M, Saluzzo S, Knapp S, et al. 2021. Interleukin-33 improves local immunity during Gram-negative pneumonia by a combined effect on neutrophils and inflammatory monocytes. J Pathol. 253:374–83.
   PubMed Web of Science ®Google Scholar
• Saikumar Jayalatha AK, Hesse L, Ketelaar ME, Koppelman GH, Nawijn MC. 2021. The central role of IL-33/IL-1RL1 pathway in asthma: from pathogenesis to intervention. Pharmacol Ther. 225:107847.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. 2021. Cancer statistics, 2021. CA Cancer J Clin. 71:7–33.
   PubMed Web of Science ®Google Scholar
• Singhal S, Stadanlick J, Annunziata MJ, Rao AS, Bhojnagarwala PS, O’Brien S, Moon EK, Cantu E, Danet-Desnoyers G, Ra HJ, et al. 2019. Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer. Sci Transl Med. 11. doi:10.1126/scitranslmed.aat1500
   PubMed Web of Science ®Google Scholar
• Sun M, Bai Y, Zhao S, Liu X, Gao Y, Wang L, Liu B, Ma D, Ma C. 2018. Gram-negative bacteria facilitate tumor progression through TLR4/IL-33 pathway in patients with non-small-cell lung cancer. Oncotarget. 9:13462–73.
   PubMedGoogle Scholar
• Talabot-Ayer D, Lamacchia C, Gabay C, Palmer G. 2009. Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem. 284:19420–26.
   PubMed Web of Science ®Google Scholar
• Talker SC, Barut GT, Lischer HEL, Rufener R, von Munchow L, Bruggmann R, Summerfield A. 2022. Monocyte biology conserved across species: functional insights from cattle. Front Immunol. 13:889175.
   PubMed Web of Science ®Google Scholar
• Tjota MY, Camacho DF, Turnquist HR, Sperling AI. 2017. IL-33 drives monocyte recruitment to lung interstitium through chemokine upregulation. Immunohorizons. 1:101–08.
   PubMedGoogle Scholar
• Torre LA, Siegel RL, Jemal A. 2016. Lung cancer statistics. Adv Exp Med Biol. 893:1–19.
   PubMed Web of Science ®Google Scholar
• Wang C, Chen Z, Bu X, Han Y, Shan S, Ren T, Song W. 2016. IL-33 signaling fuels outgrowth and metastasis of human lung cancer. Biochem Biophys Res Commun. 479:461–68.
   PubMed Web of Science ®Google Scholar
• Wang K, Shan S, Yang Z, Gu X, Wang Y, Wang C, Ren T. 2017. IL-33 blockade suppresses tumor growth of human lung cancer through direct and indirect pathways in a preclinical model. Oncotarget. 8:68571–82.
   PubMedGoogle Scholar
• Wang HM, Zhang XH, Ye LQ, Zhang K, Yang NN, Geng S, Chen J, Zhao SX, Yang KL, Fan FF. 2020. Insufficient CD100 shedding contributes to suppression of CD8(+) T-cell activity in non-small cell lung cancer. Immunology. 160:209–19.
   PubMed Web of Science ®Google Scholar
• Yang M, Feng Y, Yue C, Xu B, Chen L, Jiang J, Lu B, Zhu Y. 2018. Lower expression level of IL-33 is associated with poor prognosis of pulmonary adenocarcinoma. PLoS One. 13:e0193428.
   PubMed Web of Science ®Google Scholar
• Yeoh WJ, Vu VP, Krebs P. 2022. IL-33 biology in cancer: an update and future perspectives. Cytokine. 157:155961.
   PubMed Web of Science ®Google Scholar
• Zhang ZH, Wang H, Zhang DN, Zhu GZ. 2019. Notch signaling suppresses CD14(+) monocytes cells activity in patients with chronic hepatitis C. APMIS. 127:642–52.
   PubMed Web of Science ®Google Scholar
• Zhou X, Feng Y, Liu S, Li C, Teng Y, Li X, Lu J. 2021. IL-33 promotes the growth of non-small cell lung cancer cells through regulating miR-128-3p/cdip1 signalling pathway. Cancer Manag Res. 13:2379–88.
   PubMed Web of Science ®Google Scholar